Overall Survival Win for Osimertinib-Chemotherapy in First-Line EGFR-Mutated NSCLC

(MedPage Today) — First-line osimertinib (Tagrisso) plus chemotherapy significantly improved survival versus osimertinib monotherapy in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC).
Among a total of 557 patients, and…

Source link : https://www.medpagetoday.com/meetingcoverage/iaslc/117347

Author :

Publish date : 2025-09-08 00:32:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30

Overall Survival Win for Osimertinib-Chemotherapy in First-Line EGFR-Mutated NSCLC

First-Line Osimertinib Plus Chemo Extends Survival in NSCLC

Malnutrition and Infection Rates Increase Before IBD Surgery

Related Posts

Ocrelizumab May Double Serious Infection Risk in MS

YouTube to Bring Back Creators Banned for COVID Misinformation

Mucus-Thinning Strategies Fail for Bronchiectasis, Study Shows

Cardiovascular Exercise ‘Rewires’ the Heart, Animal Study Suggests

Two-in-one inhalers slash asthma attacks among young children

Reliever Combo Inhaler Better Than SABA Alone for Kids’ Mild Asthma

Ocrelizumab May Double Serious Infection Risk in MS

YouTube to Bring Back Creators Banned for COVID Misinformation

Mucus-Thinning Strategies Fail for Bronchiectasis, Study Shows

Cardiovascular Exercise ‘Rewires’ the Heart, Animal Study Suggests

Two-in-one inhalers slash asthma attacks among young children

Reliever Combo Inhaler Better Than SABA Alone for Kids’ Mild Asthma

Florence Welch says she had life-saving surgery after ectopic pregnancy

What Weight Loss Study Was Retracted?

Categories

Archives